Evaluation of the Safety and Effectiveness of Percutaneous and Transbronchial Argon-helium Cryoablation

Inclusion Criteria:

* Primary or metastatic lung cancer with definite pathological diagnosis
* Not suitable for thoracotomy due to serious or serious lung or systemic diseases
* Peripheral lung cancer involves pleura and chest wall, and cannot be completely removed after surgery
* There are indications for surgical resection, but the patient refuses to operate
* Single tumor, maximum diameter ≤ 5cm
* Or the number of tumors ≤ 3 and the maximum diameter ≤ 3cm
* ECOG-PS score ≤ 2
* The expected survival period is more than three months
* Those who have not participated in other clinical verifications within 3 months
* Subjects voluntarily signed the informed consent form

Exclusion Criteria:

* Serious cardio-cerebral disease or other mental diseases
* Severe pulmonary fibrosis, especially drug-induced pulmonary fibrosis
* Patients with previous severe pulmonary dysfunction, pulmonary ventilation disorder and multiple pulmonary bullae
* Have a history of immunodeficiency, including HIV test (enzyme-linked immunosorbent assay and Western blotting) positive
* Chemotherapy, radiotherapy, interventional therapy, ablation and surgical treatment within 30 days before surgical treatment
* There is a tendency to severe bleeding, and the platelet is less than 50 × 109/L and severe disorder of coagulation function
* Coagulation index (PT, TT, APTT)\>2.5 times of the upper normal limit
* Malignant pleural effusion on the same side of the ablation focus was not well controlled
* Poor general condition, multiple organ failure, cachexia, severe anemia and nutritional metabolism disorder
* Those who have extensive extrapulmonary metastasis and are not suitable for ablation treatment
* Those who often use sedatives, sleeping pills, tranquilizers or other addictive drugs
* Pregnant or lactating women
* Those who can not judge the curative effect
* Other conditions determined by the researcher to be unsuitable for the group, such as inability to tolerate cryoablation, difficulty in follow-up, and other serious diseases